RB1 and small cell lung carcinoma: The study by Budak-Alpdogan et al (10) demonstrated that sequential treatment of flavopiridol and doxorubicin induces potent in vitro and in vivo synergism in retinoblastoma protein (pRb)-negative SCLC cells and should be clinically tested in tumors lacking functional pRb.